Bayer AG ADR (BAYRY) News
Filter BAYRY News Items
BAYRY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BAYRY News Highlights
- For BAYRY, its 30 day story count is now at 18.
- Over the past 27 days, the trend for BAYRY's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about BAYRY are AG, AVEO and DRUG.
Latest BAYRY News From Around the Web
Below are the latest news stories about Bayer Aktiengesellschaft that investors may wish to consider to help them evaluate BAYRY as an investment opportunity.
The Crop Protection Toolbox: How Farmers Protect Their Crops From Monster WeedsWhether you have a meticulous front lawn accented with shrubs and flowers — or a backyard garden filled with the promise of delicious tomatoes and peppers — dealing with weeds can feel like an impossible task. |
Artificial Intelligence | Real Solutions for Plant BreedersPlant breeding today involves some of the world’s most sophisticated technologies and practices |
Bayer (BAYRY) Gets a Hold Rating from BMO CapitalE ratio…. |
Yara buys 14% stake in Brazil farm trade platform OrbiaA unit of Norwegian plant nutrition company Yara International ASA has acquired for an undisclosed sum a 14% stake in Brazilian online farm products trade platform Orbia, majority owned by Germany's Bayer AG. The move, formally announced after the parties secured approval from Brazilian antitrust authorities for the deal, comes as Yara aims to derive 25% of its sales from online channels by 2025, Yara Americas Vice President Cleiton Vargas said in an interview. "Orbia was a perfect fit," Vargas said. |
Bayer Highlights Advancements of Agriculture Industry's Most Prolific R&D PipelineIndustry-leading investment expected to translate to nearly €30bn peak sales potential |
Cost of Growing Food to Rise Even More Amid Weedkiller Supply Crunch(Bloomberg) -- A supply crunch is threatening to cause a spike in prices for the world’s No. 1 weedkiller, making it even more expensive for farmers to grow food.Most Read from BloombergElon Musk Donated $5.7 Billion of Tesla Shares to CharityTrump's Accountants Just Quit. What Took So Long?U.S. Offers Support After Banks Face Cyber Hit: Ukraine UpdatePutin Seeks Diplomatic Solution Amid ‘Partial’ Troop PullbackU.S. Accuses Zero Hedge of Spreading Russian PropagandaA major supplier of an ingredi |
Headlines of the Future: The Future of Agriculture and Climate ChangeIn the third episode Jess and Klaus dive deep into their findings on the real effects on climate change and how it is altering the world we live in. |
Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney CancerAveo Pharmaceuticals Inc (NASDAQ: AVEO) will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium. The trial is evaluating Fotivda (tivozanib) to Bayer AG's (OTC: BAYRY) Nexavar (sorafenib) in advanced renal cell carcinoma (RCC) patients following two or more prior systemic therapies. "This marks the first presentation of five-year follow-up data for pa |
How STEM Education Is Advancing AgricultureThere’s no single solution to feeding a growing population. Rather, breakthrough innovations happen where the sciences meet. Watch to see how STEM education is advancing agriculture—and help us tha... |
Bayer gets FDA fast track status for next-generation blood thinnerGermany's Bayer has won fast-track status from U.S. drugs regulators for a new blood thinner designed to prevent certain types of strokes, as it seeks to follow up on the success of its anticoagulant Xarelto. In a statement on Thursday, Bayer said the Food and Drug Administration granted fast track designation for the review of drug candidate asundexian when tested to prevent a repeat in patients that suffered a non-cardioembolic stroke from clogged vessels. Bayer's best-selling stroke prevention pill Xarelto, in which partner Johnson & Johnson holds some rights, will lose patent protection around 2026. |